AstraZeneca

China's National Medical Products Administration approved the ORPATHYS-TAGRISSO combination for treating EGFR-mutated non-small cell lung cancer patients with MET amplification after disease progression on EGFR inhibitor therapy.

The FDA has approved 84 drugs in 2025 so far, marking the second-highest total for this period despite major organizational changes including 3,500 staff layoffs.

Dicot Pharma has completed enrollment and dosing of all participants in its Phase 2a clinical trial evaluating LIB-01 for erectile dysfunction treatment.

Evotec has joined the NURTuRE-AKI consortium led by Kidney Research UK to establish the world's most comprehensive patient cohort for acute kidney injury research.

A BMJ investigation has revealed evidence of serious misreporting in two clinical trials that were pivotal to ticagrelor's approval by the FDA and UK regulators.

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, including an upfront payment of almost $1 billion and $300 million in milestone-based payments.

ANGLE presented breakthrough data at EACR 2025 demonstrating DNA dual analysis combining CTC-DNA and ctDNA from single blood samples, revealing 53% of mutations found exclusively in CTCs in lung cancer patients.

Solu Therapeutics has appointed Enda Moran, PhD, MBA as Chief Operating Officer to lead operational functions as the company advances its Phase 1 clinical trial of STX-0712.

A new comprehensive report analyzes 943 autoimmune collaboration and licensing deals from 2016-2025, covering over 30 diseases including multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease.

AstraZeneca has selected and licensed Quell Therapeutics' lead CAR-Treg cell therapy candidate for inflammatory bowel disease, triggering a $10 million milestone payment.